A comparison of cisplatin and the combination of cisplatin and cyclophosphamide in advanced urothelial cancer. A national bladder cancer collaborative group a study
- 1 September 1983
Abstract
A prospective multi-institutional randomized trial compared the use of cisplatin (DDP) alone to the combination of DDP and cyclophosphamide in patients with advanced urothelial cancer. Patients were stratified according to measurable or evaluable tumor and performance status. The dose of DDP was 70 mg/m2 and the initial dose of cyclophosphamide was 750 mg/m2. There were ten objective responders (20%), including five complete responders, among the 50 evaluable patients who received DDP alone, and seven responders (11.9%), three complete, among the 59 receiving the combination therapy. Approximately one third of the patients in each treatment arm were stable at the nine-week evaluation. There was no statistical significance between the response rates in the two treatment arms.This publication has 9 references indexed in Scilit:
- A Phase 2 Study of Cis‐platinum in Patients with Recurrent Bladder CarcinomaBritish Journal of Urology, 1981
- Methotrexate: An active drug in bladder cancerCancer, 1981
- Cis-diamminedichloroplatinum (II) in locally advanced and metastatic urothelial cancerCancer, 1981
- VP-16-213 IN THE TREATMENT OF STAGE-III AND STAGE-IV DIFFUSE LYMPHOCYTIC LYMPHOMA OF THE LARGE CELL (HISTIOCYTIC) VARIETY - AN INTERIM-REPORT1981
- PHASE-II TRIAL WITH CISPLATIN, DOXORUBICIN, AND CYCLOPHOSPHAMIDE (CAP) IN THE TREATMENT OF UROTHELIAL TRANSITIONAL CELL-CARCINOMA1981
- Cis-Diamminedichloride Platinum II in the Treatment of Abvanced Bladder CancerJournal of Urology, 1980
- Diamminedichloride platinum II and cyclophosphamide in the treatment of advanced urothelial cancerCancer, 1978
- ADRIAMYCIN AND CYCLOPHOSPHAMIDE IN ADVANCED BLADDER CANCER1977
- CIS-DICHLORODIAMMINEPLATINUM(II) IN ADVANCED BLADDER CANCER1976